Antibody screening using mammalian display can provide earlier insights into the developability of lead therapeutic molecules due to the presence of the same post-translational modifications that will occur during protein production. However, the number of clones that can typically be screened by mammalian display is too low to power antibody discovery campaigns. 

To address this challenge, OXGENE have developed a novel mammalian display system that enables the screening of over 100-fold more variants than traditional approaches.

Covered in the webinar:

• Self Labelling Integral Membrane Display (SLIM) — OXGENE’s novel method of mammalian display for antibody discovery.
• Why OXGENE chose Twist to produce their optimized scFV antibody discovery library, comprising all known human germline sequences.
• How these technologies enable screening of up to 109 biologically active variants against membrane proteins displaying only physiologically relevant epitopes.